Trials / Conditions / Recurrent Endometrial Serous Adenocarcinoma
Recurrent Endometrial Serous Adenocarcinoma
6 registered clinical trials studyying Recurrent Endometrial Serous Adenocarcinoma — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patien NCT05231122 | Roswell Park Cancer Institute | Phase 2 |
| Active Not Recruiting | Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma NCT05870761 | Casey Cosgrove | Phase 2 |
| Active Not Recruiting | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel a NCT03914612 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer NCT03325634 | University of Colorado, Denver | Phase 1 |
| Active Not Recruiting | VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer NCT03120624 | Mayo Clinic | Phase 1 |
| Unknown | Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer NCT00492778 | GOG Foundation | Phase 2 |